Shopping Cart
- Remove All
Your shopping cart is currently empty
RET-IN-23
🥰Excellent
Catalog No. T79099Cas No. 2479961-46-9
RET-IN-23 is an orally available and highly potent RET inhibitor with significant antitumor activity for the study of non-small cell lung cancer.
RET-IN-23
🥰Excellent
Catalog No. T79099Cas No. 2479961-46-9
RET-IN-23 is an orally available and highly potent RET inhibitor with significant antitumor activity for the study of non-small cell lung cancer.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $293 | In Stock | |
| 5 mg | $722 | In Stock | |
| 10 mg | $987 | In Stock | |
| 25 mg | $1,520 | In Stock | |
| 50 mg | $1,980 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "RET-IN-23"
Regorafenib
Cited
Fluoro-Sorafenib, BAY 73-4506
T1792755037-03-7
Regorafenib (BAY 73-4506) is an orally active, multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ, exhibiting both antitumor and anti-angiogenic activity.
- $30
Size
QTY
CitedRegorafenib monohydrate
T1792L1019206-88-2
Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR3, PDGFR-β, KIT, RET, RAF-1, B-RAF and B-RAF(V600E) respectively.
- $30
Size
QTY
Lenvatinib mesylate Cited
E7080 (mesylate)
T8541857890-39-2
Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.
- $34
Size
QTY
CitedFedratinib
Cited
TG-101348, SAR 302503
T1995936091-26-8
Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.
- $45
Size
QTY
CitedLenvatinib Cited
E7080
T0520417716-92-8
Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib has the strongest inhibitory activity on VEGFR2 and VEGFR3 (IC50=4/5.2 nM). Lenvatinib has strong anti-tumor activity.
- $40
Size
QTY
CitedSelpercatinib Cited
LOXO-292
T82222152628-33-4
Selpercatinib (LOXO-292) is a tyrosine kinase inhibitor with antineoplastic properties, displaying IC50 values of 14.0 nM for RET (WT), 24.1 nM for RET (V804M), and 530.7 nM for RET (G810R).
- $30
Size
QTY
CitedRegorafenib Hydrochloride
BAY73-4506 hydrochloride
T8402835621-07-3
Regorafenib Hydrochloride (BAY73-4506 hydrochloride) is a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- $30
Size
QTY
Amuvatinib Cited
MP470, HPK 56
T2516850879-09-3
Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.
- $44
Size
QTY
CitedON123300
T69201357470-29-1
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
- $39
Size
QTY
AST 487 Cited
NVP-AST 487
T4053630124-46-8
AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.
- $31
Size
QTY
CitedCabozantinib Cited
XL184, BMS-907351
T2586849217-68-1
Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM). Cabozantinib exhibits both antitumor and antiangiogenic activity.
- $39
Size
QTY
Cited
Select Batch
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | RET-IN-23 is an orally available and highly potent RET inhibitor with significant antitumor activity for the study of non-small cell lung cancer. |
| Targets&IC50 | RET (V804M):1.03 nM, RET (V804L):6.54 nM, RET (M918T):1.47 nM, RET(CCDC6):2.50 nM, RET (WT):1.32 nM |
| In vitro | RET-IN-23 is a potent and orally active RET inhibitor with IC50 of 1.32, 2.50, 6.54, 1.03, and 1.47 nM for RET-WT, RET-CCDC6, RET-V804L, RET-V804M, and RET-M918T, respectively. [1] |
| In vivo | RET-IN-23 exhibited significant antitumor activity in mice after oral administration at a dose of 5 mg/kg. [1] |
| Molecular Weight | 537.59 |
| Formula | C28H28FN11 |
| Cas No. | 2479961-46-9 |
| Smiles | FC=1C=NN(C1)C2=NC=C(C=C2)CN3C4CN(C5=NC=C(C=C5)C6=NC(=CC(=N6)C)NC7=NNC(=C7)C)CC3C4 |
Storage & Solubility Information
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy RET-IN-23 | purchase RET-IN-23 | RET-IN-23 cost | order RET-IN-23 | RET-IN-23 chemical structure | RET-IN-23 in vivo | RET-IN-23 in vitro | RET-IN-23 formula | RET-IN-23 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.